Related references
Note: Only part of the references are listed.Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection
Sunwen Chou et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
Dispirotripiperazine-core compounds, their biological activity with a focus on broad antiviral property, and perspectives in drug design (mini-review)
Anna Egorova et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients
Cameron M. Douglas et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Letermovir Resistance in Hematopoietic Stem Cell Transplant Recipients: The Risks Associated with Cytomegalovirus Prophylaxis
Scott H. James
JOURNAL OF INFECTIOUS DISEASES (2020)
Artemisinins target the intermediate filament protein vimentin for human cytomegalovirus inhibition
Sujayita Roy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Synthesis and Antiviral Properties of 1-Substituted 3-[(ω-(4-Oxoquinazolin-4(3H)-yl)alkyl]uracil Derivatives
M. P. Paramonova et al.
ACTA NATURAE (2020)
Antiviral activity spectrum of phenoxazine nucleoside derivatives
Liubov Kozlovskaya et al.
ANTIVIRAL RESEARCH (2019)
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation
Francisco M. Marty et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Phase Ib Trial To Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filociclovir (MBX-400, Cyclopropavir) in Healthy Volunteers
Nadine G. Rouphael et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections
Brian G. Gentry et al.
ANTIVIRAL RESEARCH (2019)
Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus
Esther Oiknine-Djian et al.
ANTIVIRAL RESEARCH (2019)
Full-length human cytomegalovirus terminase pUL89 adopts a two-domain structure specific for DNA packaging
Janine Theiss et al.
PLOS PATHOGENS (2019)
The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication
E. Oiknine-Djian et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Metal-chelating 3-hydroxypyrimidine-2,4-diones inhibit human cytomegalovirus pUL89 endonuclease activity and virus replication
Yan Wang et al.
ANTIVIRAL RESEARCH (2018)
Drug-resistant cytomegalovirus: clinical implications of specific mutations
Raymund R. Razonable
CURRENT OPINION IN ORGAN TRANSPLANTATION (2018)
Inhibition of Human Cytomegalovirus pUL89 Terminase Subunit Blocks Virus Replication and Genome Cleavage
Yan Wang et al.
JOURNAL OF VIROLOGY (2017)
Synthesis of Novel Hybrids of Quinazoline and Artemisinin with High Activities against Plasmodium falciparum, Human Cytomegalovirus, and Leukemia Cells
Tony Froehlich et al.
ACS OMEGA (2017)
The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitors
C. Hutterer et al.
ANTIVIRAL RESEARCH (2016)
Design, Synthesis, and Biological Evaluations of Hydroxypyridonecarboxylic Acids as Inhibitors of HIV Reverse Transcriptase Associated RNase H
Jayakanth Kankanala et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance
Sunwen Chou
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
DSTP-27 Prevents Entry of Human Cytomegalovirus
Rebekka Paeschke et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus
R. Germi et al.
ANTIVIRAL RESEARCH (2014)
Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses
Diana F. Florescu et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2014)
Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation
Roy F. Chemaly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Human Cytomegalovirus UL51 Protein Is Essential for Viral Genome Cleavage-Packaging and Interacts with the Terminase Subunits pUL56 and pUL89
Eva Maria Borst et al.
JOURNAL OF VIROLOGY (2013)
CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
Francisco M. Marty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cytomegalovirus Infections in Solid Organ Transplantation: A Review
Poornima Ramanan et al.
INFECTION AND CHEMOTHERAPY (2013)
Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation
Dana G. Wolf et al.
ANTIVIRAL RESEARCH (2011)
Antiviral Drug Resistance of Human Cytomegalovirus
Nell S. Lurain et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir
Mark N. Prichard
REVIEWS IN MEDICAL VIROLOGY (2009)
Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study
Drew J. Winston et al.
BLOOD (2008)
Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation
Michael Y. Shapira et al.
CLINICAL INFECTIOUS DISEASES (2008)
Fluoroanalogues of anti-cytomegalovirus agent cyclopropavir: Synthesis and antiviral activity of (E)- and (Z)-9-{[2,2-bis(hydroxymethyl)-3-fluorocyclopropylidene]methyl}-adenines and guanines
Shaoman Zhou et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2007)
Identification of the interaction domain of the small terminase subunit pUL89 with the large subunit pUL56 of human cytomegalovirus
Corina Thoma et al.
BIOCHEMISTRY (2006)
The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo
SJF Kaptein et al.
ANTIVIRAL RESEARCH (2006)
Antiviral drugs for cytomegalovirus diseases
Karen K. Biron
ANTIVIRAL RESEARCH (2006)
Artemisone - A highly active antimalarial drug of the artemisinin class
RK Haynes et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2006)
Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections
ER Kern et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses
SL Williams et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Binding of a N,N'-bisheteryl derivative of dispirotripiperazine to heparan sulfate residues on the cell surface specifically prevents infection of viruses from different families
M Schmidtke et al.
VIROLOGY (2003)
Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action
KK Biron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure
H Scheffczik et al.
NUCLEIC ACIDS RESEARCH (2002)
Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses
T Efferth et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2002)
Share Paper
